LXRX Financial Facts

Subscription and license fees: 31K
Total revenues: 27.72M
See Full Income Statement

Commitments and contingencies: 0
Cash and cash equivalents: 38.77M
See Full Balance Sheet

Lexicon Pharmaceuticals, Inc. (LXRX) Earnings

  |   Expand Research on LXRX
Next EPS Date 8/6/26 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate +59.6% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +3.7% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
4/30/26 Q126 N/A-$0.07 N/A N/A$5.65M N/A N/A N/A
3/5/26 Q425 -$0.04-$0.07 +$0.03$5.5M$3.92M N/A Details
11/6/25 Q325 -$0.04-$0.07 +$0.03$14.1M$4.65M N/A Details
10/30/25 Q325 N/A-$0.07 N/A N/A$4.65M N/A N/A N/A
8/6/25 Q225 $0.01-$0.09 +$0.10$28.86M$6.49M N/A Details
5/13/25 Q125 -$0.07-$0.12 +$0.05$1.26M$2.82M N/A Details
5/6/25 Q125 N/A-$0.12 N/A N/A$2.82M N/A N/A N/A
5/5/25 Q125 N/A-$0.12 N/A N/A$2.82M N/A N/A N/A